*Purpose: The aim of this study is to evaluate long term clinical outcomes in kidney transplant patients undergoing non-invasive rejection monitoring with the OmniGraf® biomarker panel (TruGraf® and TRAC™)

*Methods: The TRULO (TruGraf Long-term Clinical Outcomes) study is a prospective, multi-center, observational study evaluating quarterly surveillance and additional testing when rejection is suspected (for cause) with the OmniGraf biomarker panel, which includes both TruGraf® Gene Expression Profile and TRAC™ donor-derived cell free DNA (dd-cfDNA). The TruGraf test is a qualitative, “rule out” assay that confirms if a patient’s peripheral gene expression is similar to a biopsy confirmed phenotype of no rejection (immune quiescence). TRAC™ dd-cfDNA utilizes single nucleotide polymorphisms (SNPs) present in genes of the organ donor compared to the recipient to estimate the fraction of circulating cfDNA originating from donor. Recent data support that utilizing a combination of gene expression and dd-cfDNA may be complementary in aiding the diagnosis of subclinical rejection.

*Results: The TRULO study will collect data over a 2-year study period with 2000 subjects at about 50 US transplant centers. The primary end point is a composite of the occurrence of either biopsy proven acute rejection (on a for cause biopsy) OR a decrease from baseline in eGFR>10ml/min at 2-years post-enrollment. A key secondary endpoint is the evaluation of the clinical utility surveys performed with each set of TruGraf and TRAC results.

*Conclusions: Enrollment is competitive and site recruitment is still in process with Table 1 describing baseline demographics of the 637 enrolled subjects at time of analysis.

« Back to 2022 American Transplant Congress